ArticleFrontiers in oncology2025
The impact of demographic, clinical, and treatment factors on overall survival in ovarian carcinosarcomas: a National Cancer Database study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Ovarian carcinosarcoma is a rare and highly aggressive biphasic neoplasm, accounting for less than 1% of ovarian malignancies. This study utilizes the National Cancer Database (NCDB) to examine the impact of demographics, clinical presentation, and treatment on the overall survival of patients diagnosed with ovarian carcinosarcoma. Methods: A cohort of 420 patients diagnosed with ovarian carcinosarcoma was identified in the NCDB from 2004 to 2020. Patient characteristics and management strategies were analyzed using Kaplan-Meier survival curves, log-rank tests, and multivariable Cox proportional hazard models to determine significance. Results: Advanced cancer stage was associated with increased mortality risk, as all stage comparisons yielded significant results, ranging from a nearly two-fold increase in risk comparing Stage I and Stage II cancers (HR: 1.96; 95% CI: 1.13 - 3.40; p = 0.017) to over a four-fold increase in Stage I vs. Stage IV hazard ratios (HR: 4.27; 95% CI: 2.64-6.90; p < 0.001). Likewise, increasing Charlson-Deyo comorbidity scores exhibited a trend towards higher mortality, although only the comparison of score 0 to scores ≥ 3 was statistically significant (HR: 6.70; 95% CI: 2.06-21.80; p = 0.002). Furthermore, only select comparisons within different income classes and educational attainment reached statistical significance. Treatment modalities were found to have inconsistent impacts on survival, as primary radiation therapy was associated with unfavorable survival outcomes (HR: 1.54; 95% CI: 1.00-2.37; p = 0.049), while chemotherapy significantly improved outcomes (HR: 0.40; 95% CI: 0.31-0.52; p < 0.001). When analyzed independently, surgical resection was not significantly associated with overall survival (HR: 0.95; 95% CI: 0.51-1.81; p = 0.887). Conclusion: Tumor staging, comorbidities, and certain treatment modalities were found to be significant predictive factors of ovarian carcinosarcoma survival. Comparisons between age, race, and insurance status were not significantly associated with overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.